Impella unloading during venoarterial extracorporeal membrane oxygenation was associated with lower in-hospital mortality compared with IABP (57.3% vs 67.2%; OR 0.86, 95% CI 0.75-0.99).
Cohort (n=18,906)
Yes
Does Impella reduce in-hospital mortality compared to intra-aortic balloon pump in patients with cardiogenic shock requiring venoarterial extracorporeal membrane oxygenation?
In patients with cardiogenic shock requiring VA-ECMO, left ventricular unloading with Impella was associated with lower in-hospital mortality compared to IABP, though with longer hospital stays and higher costs.
Odds Ratio: 0.86 (95% CI 0.75–0.99)
Absolute Event Rate: 57.3% vs 67.2%
BACKGROUND: Optimal unloading strategies for patients with cardiogenic shock requiring venoarterial extracorporeal membrane oxygenation remain uncertain, particularly when comparing Impella and intra-aortic balloon pump (IABP). We aimed to compare outcomes of patients receiving Impella or IABP during venoarterial extracorporeal membrane oxygenation and evaluate cause-specific differences. METHODS: In this retrospective cohort study using the nationwide JROAD-DPC (Japanese Registry of All Cardiac and Vascular Diseases-Diagnosis Procedure Combination) database from 2012 to 2023, patients with cardiogenic shock treated with venoarterial extracorporeal membrane oxygenation and either Impella or IABP were analyzed. Propensity score-based inverse probability of treatment weighting was applied to adjust baseline differences. RESULTS: Among 18 906 patients (Impella, n=1688; IABP, n=17 218), overall in-hospital mortality was 57.3% with Impella and 67.2% with IABP. Impella use was associated with lower in-hospital mortality compared with IABP (odds ratio OR, 0.86 95% CI, 0.75-0.99). Cause-specific analyses showed significantly lower mortality with Impella in heart failure (OR, 0.66 95% CI, 0.47-0.91) and arrhythmia (OR, 0.62 95% CI, 0.42-0.91). Impella use was also associated with longer hospital stay (median, 22 versus 12 days), longer support duration (7 versus 4 days), and higher total costs (56.1 versus 27.3 thousand USD). CONCLUSIONS: In this nationwide cohort, Impella unloading during venoarterial extracorporeal membrane oxygenation was associated with lower in-hospital mortality than IABP in the overall cohort, particularly in selected causes, at the expense of prolonged hospitalization and higher costs. Further studies are needed to define optimal cause-specific unloading strategies in cardiogenic shock.
Ito et al. (Fri,) conducted a cohort in Cardiogenic shock requiring venoarterial extracorporeal membrane oxygenation (n=18,906). Impella vs. Intra-aortic balloon pump (IABP) was evaluated on In-hospital mortality (OR 0.86, 95% CI 0.75-0.99). Impella unloading during venoarterial extracorporeal membrane oxygenation was associated with lower in-hospital mortality compared with IABP (57.3% vs 67.2%; OR 0.86, 95% CI 0.75-0.99).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: